1. Home
  2. IOVA vs TXG Comparison

IOVA vs TXG Comparison

Compare IOVA & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • TXG
  • Stock Information
  • Founded
  • IOVA 2007
  • TXG 2012
  • Country
  • IOVA United States
  • TXG United States
  • Employees
  • IOVA N/A
  • TXG N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • TXG Biotechnology: Laboratory Analytical Instruments
  • Sector
  • IOVA Health Care
  • TXG Industrials
  • Exchange
  • IOVA Nasdaq
  • TXG Nasdaq
  • Market Cap
  • IOVA 1.0B
  • TXG 1.0B
  • IPO Year
  • IOVA N/A
  • TXG 2019
  • Fundamental
  • Price
  • IOVA $3.17
  • TXG $8.63
  • Analyst Decision
  • IOVA Strong Buy
  • TXG Buy
  • Analyst Count
  • IOVA 9
  • TXG 15
  • Target Price
  • IOVA $18.22
  • TXG $18.85
  • AVG Volume (30 Days)
  • IOVA 9.3M
  • TXG 3.9M
  • Earning Date
  • IOVA 05-08-2025
  • TXG 05-08-2025
  • Dividend Yield
  • IOVA N/A
  • TXG N/A
  • EPS Growth
  • IOVA N/A
  • TXG N/A
  • EPS
  • IOVA N/A
  • TXG N/A
  • Revenue
  • IOVA $164,070,000.00
  • TXG $610,785,000.00
  • Revenue This Year
  • IOVA $182.20
  • TXG $0.71
  • Revenue Next Year
  • IOVA $62.10
  • TXG $9.28
  • P/E Ratio
  • IOVA N/A
  • TXG N/A
  • Revenue Growth
  • IOVA 13698.99
  • TXG N/A
  • 52 Week Low
  • IOVA $2.70
  • TXG $6.78
  • 52 Week High
  • IOVA $13.60
  • TXG $28.25
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 43.38
  • TXG 51.19
  • Support Level
  • IOVA $3.02
  • TXG $7.72
  • Resistance Level
  • IOVA $3.73
  • TXG $8.63
  • Average True Range (ATR)
  • IOVA 0.25
  • TXG 0.43
  • MACD
  • IOVA 0.01
  • TXG 0.14
  • Stochastic Oscillator
  • IOVA 25.33
  • TXG 84.92

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Share on Social Networks: